165 related articles for article (PubMed ID: 29228662)
1. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Ock CY; Kim S; Keam B; Kim S; Ahn YO; Chung EJ; Kim JH; Kim TM; Kwon SK; Jeon YK; Jung KC; Kim DW; Wu HG; Sung MW; Heo DS
Oncotarget; 2017 Nov; 8(58):97920-97927. PubMed ID: 29228662
[TBL] [Abstract][Full Text] [Related]
2. Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Zhang P; Liu J; Li W; Li S; Han X
Cancer Med; 2018 Jul; 7(7):3178-3187. PubMed ID: 29761938
[TBL] [Abstract][Full Text] [Related]
3. [Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Yang LS; Shi CY; Liang YH; Liu T; Hou XR; Tian XD; Wang XY
Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Oct; 37(5):516-520. PubMed ID: 31721500
[TBL] [Abstract][Full Text] [Related]
4. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.
Bu LL; Yu GT; Wu L; Mao L; Deng WW; Liu JF; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
J Dent Res; 2017 Aug; 96(9):1027-1034. PubMed ID: 28605599
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Qin X; Liu C; Zhou Y; Wang G
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
[TBL] [Abstract][Full Text] [Related]
6. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Programmed Death - Ligand 1 (Pd-L1) Expression in Head and Neck Squamous Cell Carcinoma.
Unnikrishnan A; Basavaraj V
Iran J Pathol; 2023; 18(2):193-201. PubMed ID: 37600575
[TBL] [Abstract][Full Text] [Related]
8. Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
Zahnreich S; Gebrekidan S; Multhoff G; Vaupel P; Schmidberger H; Mayer A
Front Oncol; 2021; 11():623964. PubMed ID: 33718186
[TBL] [Abstract][Full Text] [Related]
9. HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.
Gomez Hernandez MP; Bates AM; Starman EE; Lanzel EA; Comnick C; Xie XJ; Brogden KA
Antibiotics (Basel); 2019 Sep; 8(4):. PubMed ID: 31554151
[TBL] [Abstract][Full Text] [Related]
10. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Heineman TE; Widman A; Kuan EC; St John M
Laryngoscope Investig Otolaryngol; 2017 Jun; 2(3):99-103. PubMed ID: 28894827
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
[TBL] [Abstract][Full Text] [Related]
12. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
13. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
García-Pedrero JM; Martínez-Camblor P; Diaz-Coto S; Munguia-Calzada P; Vallina-Alvarez A; Vazquez-Lopez F; Rodrigo JP; Santos-Juanes J
J Am Acad Dermatol; 2017 Sep; 77(3):527-533. PubMed ID: 28716437
[TBL] [Abstract][Full Text] [Related]
14. GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Lin C; Cao W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Liu Z; Peng C; Wang L; Wang X; Ji T
Oncoimmunology; 2017; 6(11):e1353860. PubMed ID: 29147602
[TBL] [Abstract][Full Text] [Related]
15. DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).
Lailler C; Lamuraglia M; Racine F; Louandre C; Godin C; Chauffert B; Galmiche A; Saidak Z
Transl Oncol; 2021 Aug; 14(8):101110. PubMed ID: 33951601
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Crosta S; Boldorini R; Bono F; Brambilla V; Dainese E; Fusco N; Gianatti A; L'Imperio V; Morbini P; Pagni F
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466794
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study.
Lu H; Kuang D; Zhou P; Zeng J; Xia Q; Wang J; Duan P; Jiang L; Zang S; Jin Y; Jiang X; Li J; Tang W; Zhou J; Chen J; Ying J
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37968103
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC.
Lin W; Chen M; Hong L; Zhao H; Chen Q
Front Oncol; 2018; 8():532. PubMed ID: 30519541
[TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
